Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Am Vet Med Assoc ; 247(1): 73-8, 2015 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-26086231

RESUMO

OBJECTIVE: To investigate the effects of insulin detemir in dogs with diabetes mellitus. DESIGN: Prospective, uncontrolled clinical trial. ANIMALS: 10 client-owned dogs with naturally occurring diabetes mellitus. PROCEDURES: Dogs were treated with insulin detemir SC every 12 hours for 6 months. Follow-up evaluations were done at 1, 2, 4, 12, and 24 weeks and included evaluation of clinical signs and measurement of blood glucose concentration curves and serum fructosamine concentrations. RESULTS: Insulin detemir administration resulted in a significant decrease in blood glucose and serum fructosamine concentrations at 6 months, compared with pretreatment values. Median insulin dosage at the end of the study was 0.12 U/kg (0.055 U/lb; range, 0.05 to 0.34 U/kg [0.023 to 0.155 U/lb], SC, q 12 h). Hypoglycemia was identified in 22% (10/45) of the blood glucose concentration curves, and 6 episodes of clinical hypoglycemia in 4 dogs were recorded. A subjective improvement in clinical signs was observed in all dogs during the 6-month study period. On the basis of clinical signs and blood glucose concentration curves, efficacy of insulin detemir at the end of the study was considered good in 5 dogs, moderate in 3, and poor in 2. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that SC injection of insulin detemir every 12 hours may be a viable treatment for diabetes mellitus in dogs. Insulin detemir dosages were lower than reported dosages of other insulin types needed to maintain glycemic control, suggesting that insulin detemir should be used with caution, especially in small dogs.


Assuntos
Diabetes Mellitus/veterinária , Doenças do Cão/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Insulina Detemir/uso terapêutico , Animais , Glicemia , Diabetes Mellitus/tratamento farmacológico , Cães , Feminino , Hipoglicemiantes/administração & dosagem , Insulina Detemir/administração & dosagem , Masculino
2.
J Feline Med Surg ; 15(2): 117-23, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23064996

RESUMO

The continuous glucose monitoring system allows generation of detailed glucose curves via measurement of glucose concentration in interstitial fluid. The conventional site for sensor placement in diabetic cats is the subcutaneous tissue of the lateral chest wall. The aim of this study was to investigate the feasibility and accuracy of sensors placed in the lateral chest wall and in two alternative sites--the dorsal neck and lateral knee fold--of diabetic cats. Initialisation was successful in 15/20 lateral chest wall sensors, 9/10 neck sensors and 3/10 knee fold sensors. Compared with the reference portable blood glucose meter, 0.8% of measurements from lateral chest wall sensors, 0.7% from knee fold sensors and 0% from neck sensors would have resulted in erroneous treatment. This preliminary study suggests that dorsal neck placement may be superior to lateral chest wall and lateral knee fold; however, further investigation with a larger number of cases would be required to confirm this finding.


Assuntos
Glicemia/análise , Doenças do Gato/sangue , Diabetes Mellitus/veterinária , Monitorização Fisiológica/veterinária , Animais , Gatos , Diabetes Mellitus/sangue , Feminino , Masculino , Monitorização Fisiológica/instrumentação , Monitorização Fisiológica/métodos , Sistemas Automatizados de Assistência Junto ao Leito , Espectrofotometria/veterinária
3.
J Am Vet Med Assoc ; 243(1): 91-5, 2013 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-23786195

RESUMO

OBJECTIVE: To determine overall survival time and identify prognostic factors associated with survival time in cats with newly diagnosed diabetes mellitus. DESIGN: Retrospective case series. ANIMALS: 114 cats with newly diagnosed diabetes mellitus. PROCEDURES: Data for analysis included history, signalment, physical examination findings, hematologic and serum biochemical data, presence of ketoacidosis, and diagnosis of concurrent diseases at initial evaluation. The effects of possible predictors on survival time were determined by calculating hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Median survival time of diabetic cats was 516 days (range, 1 to 3,468 days); 70%, 64%, and 46% lived longer than 3, 6, and 24 months, respectively. Survival time was significantly shorter for cats with higher creatinine concentrations, with a hazard of dying approximately 5% greater for each increase of 10 µg/dL in serum creatinine concentration (adjusted HR, 1.005; 95% CI, 1.003 to 1.007). Ketoacidosis was not significantly associated with survival time (HR, 1.02; 95% CI, 0.590 to 1.78). CONCLUSIONS AND CLINICAL RELEVANCE: Cats with newly diagnosed diabetes mellitus had a fair to good prognosis. High serum creatinine concentration at diagnosis was associated with a poor outcome, likely because of the adverse effects of renal dysfunction. Ketoacidosis apparently was not associated with decreased survival time, suggesting that this complication should not necessarily be regarded as unfavorable.


Assuntos
Doenças do Gato/patologia , Diabetes Mellitus/veterinária , Animais , Doenças do Gato/tratamento farmacológico , Doenças do Gato/mortalidade , Gatos , Creatinina/sangue , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/mortalidade , Diabetes Mellitus/patologia , Feminino , Insulina/uso terapêutico , Cetose/veterinária , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA